Dyskalemia was common in HF with different risk in HF subtypes. Hyperkalemia and hypokalemia were predicted by similar variables and incident dyskalemia was associated with increased mortality.
PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.
In a randomized trial, a program of supervised and home-based exercise training significantly improved exercise test duration but had no effect on clinical events with similar effects across baseline physical activity tertiles in HFrEF patients.
A post-hoc analysis of ENGAGE AF-TIMI 48 showed comparable efficacy, favorable safety, and better net clinical outcomes with edoxaban vs. warfarin in Asians, compared to non-Asians.
EAPC Position Statement states that exercise programs for diabetics are a cost effective treatment and should be reimbursed.
In patients at high CV risk, higher absolute event rates were seen across the RHR spectrum in those with diabetes, but the relative risk increase based on RHR was similar for those with and without diabetes.
A network meta-analysis compared the SBP-lowering effectiveness of commonly prescribed antihypertensive treatments with structured exercise programs.
A position paper has been published by the Sports Cardiology section of the EAPC with updated recommendations on sports-participation in patients with CAD.
In the ANITSCHKOW study, 16 weeks of treatment with evolocumab in patients with elevated Lp(a) levels, did not significantly alter arterial wall inflammation, despite lowering Lp(a) by 14%.
A prospective cohort study found that alcohol consumption of ≤7 drinks per week after the diagnosis of HF was associated with longer survival in adults with HF, compared to long-term abstinence.
In the SACRA study, treatment with empagliflozin for 12 weeks was associated with reductions from baseline in nighttime, clinic, 24-hour ABP and morning HBP in T2DM with uncontrolled nocturnal hypertension.
The working group on atherosclerosis and vascular biology of the European Society of Cardiology published a position paper, which provides consensus statements on how to identify anti-inflammatory effects of lipid-lowering therapy.